<SEC-DOCUMENT>0001354488-15-002247.txt : 20150511
<SEC-HEADER>0001354488-15-002247.hdr.sgml : 20150511
<ACCEPTANCE-DATETIME>20150511095412
ACCESSION NUMBER:		0001354488-15-002247
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20150511
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20150511
DATE AS OF CHANGE:		20150511

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CEL SCI CORP
		CENTRAL INDEX KEY:			0000725363
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				840916344
		STATE OF INCORPORATION:			CO
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-11889
		FILM NUMBER:		15849192

	BUSINESS ADDRESS:	
		STREET 1:		8229 BOONE BLVD .
		STREET 2:		SUITE 802
		CITY:			VIENNA
		STATE:			VA
		ZIP:			22182
		BUSINESS PHONE:		7035069460

	MAIL ADDRESS:	
		STREET 1:		8229 BOONE BLVD.
		STREET 2:		SUITE 802
		CITY:			VIENNA
		STATE:			VA
		ZIP:			22182

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INTERLEUKIN 2 INC
		DATE OF NAME CHANGE:	19880317
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>cvm_8k.htm
<DESCRIPTION>CURRENT REPORT
<TEXT>
<html>
<head>
    <title>cvm_8k.htm</title>
    <!--Licensed to: Issuer Direct Corp.-->
    <!--Document Created using EDGARizerAgent 5.5.0.0-->
    <!--Copyright 1995 - 2014 Thomson Reuters. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="4">
<hr style="MARGIN-TOP: -10px; COLOR: #000000" noshade size="1">
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 18pt; FONT-WEIGHT: bold">UNITED STATES</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 18pt; FONT-WEIGHT: bold">SECURITIES AND EXCHANGE COMMISSION</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Washington, D.C. 20549</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 18pt; FONT-WEIGHT: bold">FORM 8-K</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">CURRENT REPORT</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">PURSUANT TO SECTION 13 OR 15(d)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">OF THE SECURITIES EXCHANGE ACT OF 1934</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Date of Report (Date of earliest event reported): May 11, 2015</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 24pt; FONT-WEIGHT: bold">CEL-SCI CORPORATION</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(Exact name of registrant as specified in its charter)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>

<div align="center">
<table cellpadding="0" cellspacing="0" width="80%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="middle" width="30%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="middle" width="30%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="middle" width="30%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="top" width="30%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Colorado</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>
</div>
</td>
<td valign="top" width="30%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">001-11889</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>
</div>
</td>
<td valign="top" width="30%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">84-0916344</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>
</div>
</td>
</tr><tr>
<td valign="top" width="30%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(State or other jurisdiction</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">of incorporation)</font></div>
</td>
<td valign="top" width="30%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(Commission File No.)</font></div>
</td>
<td valign="top" width="30%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(I.R.S. Employer</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Identification No.)</font></div>
</td>
</tr><tr>
<td valign="middle" width="30%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="middle" width="30%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="middle" width="30%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="top" width="30%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="30%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">11601 Wilshire Blvd., Sixth Floor</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Los Angeles, California 90025</font></div>
</td>
<td valign="bottom" width="30%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="top" width="30%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="30%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(Address of principal executive offices, including Zip Code)</font></div>
</td>
<td valign="top" width="30%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Registrant&#8217;s telephone number, including area code: (703) 506-9460</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Not Applicable</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(Former name or former address, if changed since last report.)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 27pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Wingdings">&#168;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 27pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Wingdings">&#168;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 27pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Wingdings">&#168;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 27pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Wingdings">&#168;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="1">
<hr style="MARGIN-TOP: -13px; COLOR: #000000" noshade size="4">
</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">&#160;</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Item. 8.01&#160;&#160;&#160;&#160;Other Events.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On May 11, 2015, CEL-SCI Corporation (&#8220;CEL SCI&#8221; or the &#8220;Company&#8221;) issued a press release announcing that Spain&#8217;s Agency for Medicinal Products and Medicinal Devices has authorized the Company to commence patient enrollment for its ongoing Phase 3 trial of its investigational immunotherapy Multikine (Leukocyte Interleukin, Injection) in patients with advanced primary squamous cell carcinoma of the oral cavity/soft palate, a type of head and neck cancer. Spain is the 22nd country to authorize CEL-SCI&#8217;s Phase 3 trial for patient enrollment.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">CEL-SCI recently announced it had reached a key milestone of receiving authorization to conduct the Phase 3 study from 21 countries, as originally planned. The Company is aiming to expand the trial into a total of approximately 100 clinical centers in about 25 countries. As of April 30, 2015, 437 patients had been enrolled in the global Phase 3 study.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">A copy of the press release is furnished herewith as Exhibit 99.1.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Forward-Looking Statements</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">This report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. When used in this press release, the words &#8220;intends,&#8221; &#8220;believes,&#8221; &#8220;anticipated,&#8221; &#8220;plans&#8221; and &#8220;expects,&#8221; and similar expressions, are intended to identify forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Factors that could cause or contribute to such differences include, an inability to duplicate the clinical results demonstrated in clinical studies, timely development of any potential products that can be shown to be safe and effective, receiving necessary regulatory approvals, difficulties in manufacturing any of the Company's potential products, inability to raise the necessary capital and the risk factors set forth from time to time in CEL-SCI Corporation&#8217;s filings with the Securities and Exchange Commission, including but not limited to its report on Form 10-K and 10-K/A for the year ended September 30, 2014. The Company undertakes no obligation to publicly release the result of any revision to these forward-looking statements which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 63pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Item&#160; 9.01</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Financial Statements and Exhibits.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 61.2pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(d)&#160;&#160;&#160;&#160;Exhibits</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="12%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Exhibit No.</font></div>
</div>
</td>
<td valign="top" width="66%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Description</font></div>
</div>
</td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="top" width="12%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">99.1</font></div>
</td>
<td align="left" valign="top" width="66%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Press release dated May 11, 2015</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">2</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">SIGNATURE</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">Date: May 11, 2015</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
<div>
<table border="0" cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="top" width="38%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold"> </font></font>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">CEL-SCI CORPORATION</font></font></font></div>
</td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="35%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td align="left" valign="top" width="50%" style="BORDER-BOTTOM: #ffffff solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td valign="top" width="3%" style="BORDER-BOTTOM: #ffffff solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">By: </font></div>
</td>
<td align="left" nowrap valign="top" width="35%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">/s/&#160;Patricia B. Prichep</font></td>
<td valign="top" width="12%" style="BORDER-BOTTOM: #ffffff solid"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" nowrap valign="bottom" width="35%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Patricia B. Prichep</font></td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="35%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> </font>
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Senior Vice President of Operations</font></font></div>
</td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="35%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr></table>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">3</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<hr style="COLOR: black" noshade size="2">
 &#160;</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>cvm_ex991.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<html>
<head>
    <title>cvm_ex991.htm</title>
    <!--Licensed to: Issuer Direct Corp.-->
    <!--Document Created using EDGARizerAgent 5.5.0.0-->
    <!--Copyright 1995 - 2014 Thomson Reuters. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
<div style="TEXT-ALIGN: right"><font style="FONT-WEIGHT: bold">Exhibit 99.1</font></div>

<div>&#160;</div>

<div>&#160;</div>

<div align="center">
<table bgcolor="white" cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td width="50%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;<img src="logo.jpg" alt=""></font></td>
<td width="50%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;<img src="release.jpg" alt=""></font></td>
</tr><tr>
<td width="50%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">8229 Boone Boulevard, Suite 802</font></font></div>
</td>
<td width="50%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">COMPANY CONTACT:</font></font></div>
</td>
</tr><tr>
<td width="50%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Vienna, VA&#160;&#160;22182.&#160;&#160;USA</font></font></div>
</td>
<td width="50%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Gavin de Windt</font></font></div>
</td>
</tr><tr>
<td width="50%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Telephone: (703) 506-9460</font></font></div>
</td>
<td width="50%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">CEL-SCI Corporation</font></font></div>
</td>
</tr><tr>
<td width="50%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">www.cel-sci.com</font></font></div>
</td>
<td width="50%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(703) 506-9460</font></font></div>
</td>
</tr></table>
</div>

<div>&#160;</div>

<div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt; FONT-WEIGHT: bold">CEL-SCI RECEIVES AUTHORIZATION TO CONDUCT ITS PHASE 3 MULTIKINE TRIAL IN SPAIN</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Spain is 22<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">nd</font> country to authorize CEL-SCI&#8217;s trial for patient enrollment</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Vienna, VA, May 11, 2015 --</font> CEL-SCI Corporation<font style="DISPLAY: inline; FONT-WEIGHT: bold"> (NYSE MKT: CVM) </font>(&#8220;CEL SCI&#8221; or the &#8220;Company&#8221;) today announced that Spain&#8217;s Agency for Medicinal Products and Medicinal Devices has authorized the Company to commence patient enrollment for its ongoing Phase 3 trial of its investigational immunotherapy Multikine* (Leukocyte Interleukin, Injection) in patients with advanced primary squamous cell carcinoma of the oral cavity/soft palate, a type of head and neck cancer. Spain is the 22<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">nd</font> country to authorize CEL-SCI&#8217;s Phase 3 trial for patient enrollment.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">CEL-SCI recently announced it had reached a key milestone of receiving authorization to conduct the Phase 3 study from 21 countries, as originally planned.&#160;&#160;The Company is aiming to expand the trial into a total of approximately 100 clinical centers in about 25 countries. As of April 30, 2015, 437 patients had been enrolled in the global Phase 3 study.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">About the Multikine Phase 3 Study</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Multikine Phase 3 study is enrolling patients with advanced primary squamous cell carcinoma of the head and neck. The objective of the study is to demonstrate a statistically significant improvement in the overall survival of enrolled patients who are treated with the Multikine treatment regimen plus standard of care (&#8220;SOC&#8221;) vs. subjects who are treated with SOC only.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">About Multikine</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Multikine (Leukocyte Interleukin, Injection) is an investigational immunotherapeutic agent that is being tested&#160;&#160;in an open-label, randomized, controlled, global pivotal Phase 3 clinical trial as a potential first-line treatment for advanced primary squamous cell carcinoma of the head and neck. Multikine is designed to be a different type of therapy in the fight against cancer: one that appears to have the potential to work with the body&#8217;s natural immune system in the fight against tumors.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Multikine is also being tested in a Phase 1 study under a Cooperative Research and Development Agreement (&#8220;CRADA&#8221;) with the U.S. Naval Medical Center, San Diego, as a potential treatment for peri-anal warts in HIV/HPV co-infected men and women.&#160;&#160;CEL-SCI has also entered into two co-development agreements with Ergomed Clinical Research Limited to further the development of Multikine for cervical dysplasia/neoplasia in women who are co-infected with HIV and HPV and for peri-anal warts in men and women who are co-infected with HIV and HPV.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">--- more ---</font></font></div>
</div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">CEL-SCI Corporation</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">May 11, 2015</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Page 2</font></font></div>
</div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">About CEL-SCI Corporation</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">CEL-SCI&#8217;s work is focused on finding the best way to activate the immune system to fight cancer and infectious diseases. Its lead investigational therapy, Multikine (Leukocyte Interleukin, Injection), is currently being studied in a pivotal Phase 3 clinical trial as a potential neoadjuvant treatment for patients with squamous cell carcinoma of the head and neck. If the study endpoint, which is a 10% improvement in overall survival of the subjects treated with the Multikine treatment regimen plus the current SOC as compared to subjects treated with the current SOC only, is satisfied, the study results will be used to support applications that the Company plans to submit to regulatory agencies in order to seek commercial marketing approvals for Multikine in major markets around the world. Additional clinical indications for Multikine that are being investigated include the treatment of cervical dysplasia in HIV/HPV co-infected women, and the treatment of peri-anal warts in HIV/HPV co-infected men and women. A Phase 1 trial of the former indication has been completed at the University of Maryland. The latter indication is now in a Phase 1 trial in conjunction with the U.S. Naval Medical Center, San Diego, under a CRADA.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">CEL-SCI is also developing its pre-clinical L.E.A.P.S. (Ligand Epitope Antigen Presentation System) technology for the potential treatment of pandemic influenza in hospitalized patients and as a potential vaccine for the treatment of rheumatoid arthritis.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Company has operations in Vienna, Virginia, and in/near Baltimore, Maryland. For more information, please visit <font style="DISPLAY: inline; FONT-SIZE: 10pt; TEXT-DECORATION: underline">www.cel-sci.com</font>.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Forward-Looking Statements</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. <font style="FONT-STYLE: italic; DISPLAY: inline">When used in this press release, the words &#8220;intends,&#8221; &#8220;believes,&#8221; &#8220;anticipated,&#8221; &#8220;plans&#8221; and &#8220;expects,&#8221; and similar expressions, are intended to identify forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Factors that could cause or contribute to such differences include, an inability to duplicate the clinical results demonstrated in clinical studies, timely development of any potential products that can be shown to be safe and effective, receiving necessary regulatory approvals, difficulties in manufacturing any of the Company's potential products, inability to raise the necessary capital and the risk factors set forth from time to time in CEL-SCI Corporation&#8217;s filings with the </font>Securities and Exchange Commission<font style="FONT-STYLE: italic; DISPLAY: inline">, including but not limited to its report on Form 10-K and 10-K/A for the year ended September 30, 2014. The Company undertakes no obligation to publicly release the result of any revision to these forward-looking statements which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">*Multikine is the trademark that CEL-SCI has registered for this investigational therapy, and this proprietary name is subject to FDA review in connection with the Company&#8217;s future anticipated regulatory submission for approval.&#160; Multikine has not been licensed or approved<font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>for sale, barter or exchange<font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>by the FDA or any other regulatory agency. Similarly, its safety or efficacy have not been established for any use. Moreover, no definitive conclusions can be drawn from the early-phase, clinical-trials data involving the investigational therapy Multikine (Leukocyte Interleukin, Injection). Further research is required, and early-phase clinical trial results must be confirmed in the Phase 3 clinical trial of this investigational therapy that is currently in progress.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"># # #</font></div>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>logo.jpg
<TEXT>
begin 644 logo.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``(!`0(!`0("`@("`@("`P4#`P,#
M`P8$!`,%!P8'!P<&!P<("0L)"`@*"`<'"@T*"@L,#`P,!PD.#PT,#@L,#`S_
MVP!#`0("`@,#`P8#`P8,"`<(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`S_P``1"`!K`-\#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#]_****`"B
MBB@`HHHH`****`"BBB@`HHHH`****`"BBC.*`"BD!S2T`%%%%`!1110`4444
M`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4456U>S;4M)NK=)7
MMWGB>-95^]$2"`P]QUIK5ZBDVDVE<Y73OVB/`NK^/W\+6WBO0I_$,;&-K!+M
M#-O'5`,\L.ZCGVK5^)MUKEK\/-;D\,PV]QXACLI6TV*X.(Y+C8=@;VW8ZU^<
M?P\_X)H?%?2/CSIL5S:16FG:9J45T^O+=H8VCCD#^8@SO,AQP".IY]:_3=1N
MKZ?B'+,!EU6E]1KJLFKO;1^=N_;='YIP#Q+GN?X7%+.L%+!N,G&.Z;33U7,M
MX_S+W6]MF>+_`+#NO_%;Q!\/-2E^*]G]DU);XK8F6&.&>2':,[TC^4`-D*>I
M'X&O:Z15VTM>#CL4L37E74%#F?PQ5DO1'W&2Y;++\#3P4ZTZK@K<\W><O-OK
M_D%%%%<IZ@4444`%%%%`!1110`4444`%)WKX@_X*$_MY>,OA?\8E\#>"KFWT
MHVEO"]Y>M`LLTLLHW*B[P550I7G&26ZC%4?^%7_MCMS_`,)+%@\_\?UG_P#&
MZ^OH\'5GAJ>*Q->G2517BIR:;7?9GY-C/%S"1S+$99EV!Q&*EAWRU'2@I1C+
M7362?1K;H['W:*,U\)_\*M_;'_Z&2/\`\#[/_P"-U4UWP7^V!X6T2\U.[\31
MK:Z=`]U,1>V;$(BEFX\OG@'BKCPC3D[+'4+_`.-__(F<_%7$0BYSR7&I+?\`
M=1V_\#/O=3D4M?(7_!-7]MOQ/^T-KNL^&?%TEM?7UA:+?6=]'"L+RQ[@CHZK
MA2064@@#J<U]2^-?'NC?#C0GU37M4L='TY'6-KF[F$4:LQPHR>,D]*\+-<FQ
M.7XQX&NKS5MM;WVL?:<+\89;GV4QSK!RM2=[\UHN/*[/FULK>MC8HKS8?MA_
M"O\`Z*#X3_\`!E'_`(T?\-A_"O\`Z*#X3_\`!E'_`(UA_9F,_P"?4O\`P%_Y
M'?\`ZRY1_P!!5/\`\#C_`)GI-%>;?\-A?"P_\U!\)_\`@QC_`,:[7P]XQTOQ
M;X:@UG3-0M;_`$FYC,T5W!('AD09!8,.,<'\JQJX/$4E>K!Q7FFCJPN;X'%2
M<,-6A-K5J,D].^C-2BN/\"?'SP5\3]8?3_#WBK0]:OHXS,T%G=I*ZH"`6(!Z
M9(_.NO4Y%9U:-2E+EJ1:?FK'1A<90Q,/:X::G'O%IK[T>.?MK_M7I^R;\+X-
M5BL4U/5]4N?L>GV\C%8MP4LSN1SM4#H.22!QUKPW]C;_`(*>ZU\8_B]8^$O&
M&E:5"=;9HK&\T]'C\N4*6"2(S-D,`0&!&#C(YX^@_P!K7]ES2_VK?AL-#OKJ
M73;RSG%W87T:;S;R[2IW+QN1@2",CL0>*\;_`&2?^"84/P"^)MMXK\0>((=>
MOM+W'3K>VMC##$[*5\QRQ)8@$X`P`3GG%?<935X=6258XQ?[3K;>]_LV>UN]
M_/R/Q;BC#<?RXSPU3*9+^S_<YM8\MO\`EYSI^\V]>6WE:SN?6NRE`Q4:W2-.
M8PZ&11ED##<!]*DZU\&?N":>PM%>:?MA?'T_LQ?LX>*/&T5M%>W>CVR_9+>4
MD)-/(ZQQAL<[=S@G'.`:_/\`^"_Q4_;'_;)\,W?BKP=XKL(]+AO7L72,V=DL
M<JJK%51HV;`#K@DG/K32N,_4NBOSC_X4_P#MY_\`0W6O_@PL/_C5'_"G_P!O
M/_H;K7_P86'_`,:I\OF!^CE%?E]9_MU?M!_L4_M$>'?"WQ?U+3=?L-5:WEN[
M9E@DDCMII3%YD<T2KAU(8[6R#CWS7Z@"DU8!:*P?'OQ2\-?"O3EN_$WB#1M`
MMI"0DNH7D=LLA'4+O(R?I7%?\-P_!W_HIW@?_P`'$'_Q5(#U.BO+/^&X?@[_
M`-%.\#_^#B#_`.*K9\$?M.?#KXE:NNGZ!XY\*:Q?R'"6UIJD,DTG^Z@;)_`4
M68'=45#J.HP:1I\]W=31V]M;1M--+(VU(D499B3T``))KE?AS^T#X&^+^HSV
MGA7Q=X>\175K$)YHM.OX[AXHR<!B%)P,G&:`/S9_X*/_`/)]6N?[VG_^B8J_
M52/_`%8^E?E7_P`%'O\`D^K7/][3_P#T3%7ZJ1G]VOTK]'XU_P"17EG_`%[?
MY0/YW\&?^2FXD_Z_K_TJJ.K)\=>'#XQ\%:OI`E\C^U+&:S\W;N\OS$*;L=\9
MSBM:L;XA^(I/"'@+6]6A1)9M+L)[N-'SM=HXV<`XYP2*_/*7-[2/)O=6]3^@
M,9[/V$_;?#9W]+:_@>&_L@_\$^-._9.\8W&NQ^);_6[^ZL38NCVR00JI96)`
M!)SE1U-5?^"L'_)GE_\`]A2R_P#1M4_V(/\`@H3>?M6^.+OP_J'AFVTBZM=/
M:^^TVUX9(WPZ*5V,H(^_GJ>E7/\`@K!_R9W?_P#84LO_`$;7W-*.91XGPZS9
MWJ\\.VU]/AT/Q/$U.':GAQCY<+*V&]E5MI)>];WOCUN>$_\`!//]B+P#^T=\
M$;W7/$]EJ,^H0:M+9HT%])`OEK'$P^5>,Y9N:]X_X=1?!S_H&:W_`.#:;_&O
MEG]B[]A34/VF/A5=:]:^.]0\-1V^HR69M((7=7*I&V_(D49.['3MUKUQ_P#@
MD3K10C_A;FL\C'_'I)_\?KZ3/L;RYC6C_:LJ?O/W5&?N^6CM]Q^><#9.ZF08
M2I_JQ3Q%X+]XZE%.?]YJ2OKYZGI1_P""4?P<_P"@9K?_`(-IO\:]B\-?#32_
M@]\%O^$:T2.6+2M(T^:&V260R.%(9N6/)Y)K?\):(WAGPMIFG/,URVGVD5L9
MF&#*40+N/7KC/7O2^+3_`,4IJ?\`UZ2_^@&OS7%9QCL7*-/$UI5(IZ7;?SU/
MZ+RSA+)LKISQ&782G0G*#3Y8I.V]FUNKGYP?\$?U'_#3^I_]@&?_`-'0U^F%
M?F?_`,$?_P#DY[4_^P#/_P"CH:_3`'-?4^)?_(Z?^&/Y'YG]'/\`Y(]?]?:G
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M?I7V[X`\"Z;\,_!FF:!H]L+32](MUMK:('.U%'<]R>23W)-?H7B%Q!E&84*4
M,#[TT[W2:M&VVJ76WI8_`_`3@/BK(<;BJV=)TZ,HV4')2YIW7O:-I65U?=W/
M"O\`@K)X;N_$W[!7CE+.)YGLTMKV14&3Y<5S$[G'LH)/L#7R;_P2V_X*"_#/
M]E;]GO4O#_C#4=2M=3NM<GOXTM]/DN$,3Q0JIW*",Y1N/I7Z&?&[XY^"?@5X
M82]\=:]I6A:9?LULAOCE;H[260)@E_ESD`'BO&_`_P"Q#^S7^TGX3M/&FA^`
MM"O]*UO?+;W-NEQ9),`[(Q$09-HW*W\(K\M3TLS^GC+_`.'SWP)_Z#6N_P#@
MEG_PH_X?/?`G_H-:[_X)9_\`"NI_X=6_`#_HG&F_^!EU_P#':/\`AU;\`/\`
MHG&F_P#@9=?_`!VCW0./\#_M2_LN?M7?&[3KV0:#J7CB9(['3Y->TITDD"LS
M)'$9E\O=N8X`^8D\9KZSK\</^"KGP-\*?LQ?M,>&].\":1%X=LCI$&HF."61
M_P#2!<R`29=F(/R+T/:OV#\.W;W_`(?L9Y#F2:WCD8^I*@FAH#\DO^"O5]-X
MQ_X*(6VCZA+)/IUI:Z79P0ECB&.9@TFWT+%CR/;TK[+_`.'+GP'_`.@)KO\`
MX.KC_P"*KXO_`."J?_*38?\`<$_FE?K]3>B0'RC_`,.7/@/_`-`37?\`P=7'
M_P`57QE^W]^P3=?`W]HS0--^#7@_QC>P)I4.I>=9QW%\\-V)Y`")<'80$0XS
M[]Z_7NO%?V@/V_\`X:?LO_$>S\,>-=3OM*OKZR6_BE6PEG@\IG=!ED!(.4;C
M'I238'8_%*:YNOV:_$<EZA2[D\,W+3JPP5D-JVX$?7-?G'_P0&4+\>O&>`/^
M1:B[?]/"5^DGQGOXM5_9_P#%=U`_F07/AZ\EC?&-RM;.0?R-?FY_P0(_Y+UX
MS_[%J+_TH2A?"P/:O^"B?[#/C7XB_&?_`(3KP98IK:7EO`MW:)*B7$$T0VA@
M'(#J5"]#D$'CFJ/_``N[]L%./^$2EXXXT>#_`.+KZXO_`(\I#XSU/1K'PIXO
MUIM&N8[.[N[&V@-M'*\4<N-SS*QPDJ$X7OWKN;J]@LDW32Q1`8!+N%`).!U]
M37V%#C*JL-3PN*P].JJ:M%RBVTOO\D?D.-\(L/+,L1F>6X_$866(ES35*:47
M+77X;]6]WN['P</CC^V%_P!"E-_X)X/_`(NJFN_%+]KKQ7H=YIEUX0F:VU&"
M2UF`TF!24=2K<[^.">:^_H;N*:XEB22-I8<>8BL"T>>1D=LTR+4()[DPI-"\
MJJ'9`X+!3T.,YQ[U:XOH)W6`HW_PO_,SGX48R<7">>8QI[_O%_\`(GR'_P`$
MR_V+?%/P$UW6?%/BZUCTR[O[-;&SL?.665$+AW=RI*K]U0!DGKG%>D_\%(/A
MQKOQ5_9?O='\.:7=:QJCZA:2K;6X!<JLF6/)'05[J+V$7?V?S8_/V^9Y6X;]
MN<9QUQ[T[ST;^(<DKU[CM]:\K$<28JOFL<VJI.<6FET]W9=[?,^DP'AUEF"X
M9GPMA7)49QE%R;3G[][N]K7U[6/SL_9RU#]H_P#9B\"S^']`^&$EQ9W%X]ZS
MWMKODWLJJ0"LJC&$';UKO_\`AI[]JO\`Z)39_P#@"_\`\?K[1GOX+.W::6:*
M*)#AG=P%7G'4\=:?)<)`-SLJ#!.6..`,G]!7IXGBVCB*LJ];!4I2EJV^;5_^
M!'SN7>%.*P&&A@\'G&)A3@K1BG3LEV^`^*_^&GOVJ_\`HE-G_P"`+_\`Q^OI
M3X/>(/%OCO\`9_@O/&.D+I'BJ]M+A;JPC0IY;;G5``6;&5"GKWKMH]96;5Q:
MK#.R-;BX6Y"@P,"V-H;/WN_3&.]317L$UP8DFB>55#E`X+!3T./0^M>1F.<4
M<3!1I8:%)IWO&]_35O0^JR#A'%Y?6G4Q.8UL1&47'EJ.-E>WO+EBM=+?-GY?
M?L[?"/X^?LS>.9_$'A_X<:A->W%H]DRWEN)(]C,K'`$BG.4'>O;!^TK^U?\`
M]$OL_P#P7G_X_7VH=4MDN6A-Q`)D`9HS(-R@G`)&<\YJ#Q3XBM_"'AG4=7N]
M_P!DTNUENYO+7<^R-"[8'<X!KW<;QK'&5/;8K!TI2VN^;I_V\?%9/X-SRG#_
M`%3+<VQ-*G=OEBX6N]W\!\9?\-*_M7_]$PM/_!>?_C]?1W[)_C3Q[X]^&,M[
M\1M#C\/^(!?2Q+;)"8@8`%V-C<W4EN_:O0M.UVVU/1K?4%?R[>ZMUN4,GRD(
M5#9//&`>?2I(]0MY9D19X6>1/-10X+.G]X#N/>O$S+.:&*H^RIX6G3=]XWOZ
M:MGV/#W!^,RW%_6:^95\0K-<E1Q<=>ND4[KIJ6:*A;4(4F2,RQB24D(A<;G(
M&2`.^!20ZC!<P&2.:*2-25+JX*@C@@GVKP3[H^<_^"H'[(&L_M??`6TL/#36
MO_"1^']074;.&XD\J.[!1DDBWGA20V03QE<'&<U\D_"K6?VTOV<OA]IO@SP_
MX&D31M#1XK93IMM=$!G9SF02_-\S&OU&,ZAB-PR!DC/0>M,AOX;B9XXY8W>+
M!=5<$IGD9';--2Z`?FY_PT/^W7_T)#_^"*W_`/CE'_#0_P"W7_T)#_\`@BM_
M_CE?I)%>Q3W$D221O+#CS$5@6CSR,CJ,UC_$CQ_:?##P;=:W>P7ES!:M$GDV
MJ!YI7DD2)%4$@9+.HY(%/F\@/S`US]C7]I#]O/XWZ%J_Q,\/V_A^ULDBL[G4
M9T@M1%:+*9&"PH[,\AW-CC'(R0!7ZL6EJEC:10QC;'"@1!Z`#`KE/!WQCL?%
M?BF70KC3]8T'6TMS>)9:G;K&]Q`"%:2-D9XW"LRAMK$KN7(&1GJH[Z&6>2)9
M8VEAQYB!@6CSR,CMFDW<#\Z_^"HW[!?Q*^(?[3-I\2?`FBCQ-:R6UH)[:*:-
M9[:>V;Y<H[+O1@%Y4YR#QT-:I_:Z_;1S_P`D8TW_`,`'_P#DBON#P)\4--^(
MMSK0TY+DP:'?/ITMS(JK#/+'Q)Y9W$D*V5)(`R#C(YK>@OX;JV6:*6.2%^5D
M1@5;MP>E._<#X`_X:Z_;1_Z(QIW_`(`/_P#)%>0?&+]EO]I+_@H)\:-'U3QC
MX"M?"GV>VCTV6\8I;6UO;B5G9RID=W8;VX4<X`XK]7[:]AO58PRQRA&*,48-
MM8=0<=Q265_!J,/F6\T4Z9*[HW##(ZC(HY@.8^)'A>4_`O7M%T^.2ZG_`+!N
M+&VC'WYF^SLB*/<G'YU\+?\`!&/]EOXB?`3XQ^*K_P`9^$-7\.6=YH,=M!->
M*@6643JQ088\X!-?HC:WT-_&6AECF4,5+1L&`(ZCCO26=]!J4/F6\L4\>2NZ
M-PPR.HR*5]+`>#G1Y/!/Q_\`%VM7GA+XC:G)=ZK!>6$^CW3?V?-$+*WB^>'[
M0B,P=)`=Z'H.O%:_Q8^"2?$?XB^+-2OO#\.J0S^#8[#36N4611=>9=L552<!
MQOC^;'&>#UKV>BD!XW\'_@P?A[\0O"5]:Z(FG)_PA\EGK%PF-\]YYMHRB9LE
MI'XG(9L]6YYY\\_9N\*G7/#?PVDT3P?=Z/J&F7LM_J7B!HH4AN[0_:%=!*K%
MY3*S)^[(^7&2%VKGZGJ&PT^#2K1+>UABMX(QA(HD"(@]@.!0!X$/AKJL?C'[
M,OA>Z_X2D^+SK!\4X3RO[.^T;]OG;M__`![?Z-Y&,9YQM^:J7Q?^"WC6+XEZ
MUJGARQ^U:?H$@\9:!`MWY0OM8=5AFM'&>$:*.4Y/&Z\)_AKZ0HH`^>OB-\#]
M9T3P5\.[9%O]2L-`CN6UJ"TLH-0DGO)T#?:#!-E)`)3-ZLOG9'`)%UO@#+XE
M\"?"?1-6TW5+[3-$U::[U&VU&:)I(X#:W@CCG$1\MHPTD2>6NY<!5.0":]XH
MH`X*S\'W5A^T2NI0V7DZ+%X773XY$"K&DBW)81A1TPF.V,5Y]\&/@+<?#]?A
M-=Q>'8=,U*PMKN/7[B)46;]Y;MA97!RX,NT@9(!`Z8KWZB@#Y`^&;0ZO\2M$
MU#Q%HVG0Z*_C"]ETO68[*&YOM2N))[B."*YF$QD"`N,9A&/+B!V;-Q^G/B_H
M]SXA^$OBC3[*)I[R^TB[MX(E(!DD>%U51GCDD"I[?X:>'+3Q.VMQ:!HL>LLQ
M8WZ648N23P3YFW=DYY.:W*`/(O$?PA?QAXF^%:ZKHT>H:9H5A=+J$<X5XH93
M;1(@=2</\P88P1Q]*YKX=_L\'P7I?@.[M/#4%CK&F^*[V>\N$5?/M[!_MZQK
MOSD0['@`C!V@;?E&./H*B@#YX\4?LW?\)':>+[RY\-1W6K:GXZL[ZVN&(\\V
M*RV0D>-]VZ-?+28,%*D@-D'/.AXF^!U_8^$_C+I'A[0X+&SUZV@;2+6WV007
M,HLU638HPJL74*20,G!/K7N]%`'CFE1:YX_^(/BW7/\`A&=9T6QO_"4&FV0U
M'RDGN)UENV93&KMLQYB?>/.<]*K_``>^"3?#?Q%\.+BQT"WTG[-X4FL=<E@1
M$9[C;9E$F(.9"&2;!.<?-SSS[710!\W_`+./P=U_PE\1-%DUB#Q$-3T>.\75
M+XVMG!9W[2YY:=?WUT';;(H/*$?-@C!]4_:5T6^U_P"#FH0:;97.HW:W-E<+
M;6X!EE6*\AE<*"0"=B,<9&<5WE%`'EFGV6K?%7XW>'_$DNA:GX>T;PI8WL<;
MZCY:7.H3W/E+M6)68K&BQDEF(+,RX&%)K@OV>?@YKWA;XBZ/)K5OXA_M/21>
M_P!IWWV6SALK\R[N6G7]]=!R5=5/*%1NQC!^D**`/GR\^`>I:7\!/&6DZ'H\
M.D7>I>*Y]1>WLH($?4;`:@)-@!PC;[<%55^"#M.`355/@YJFJ_`'QWIUKIFN
ML/$-Y;/;V%];6M@)%1H1*T=O#A858(=V[#,5+8&>?HVB@#R)/@Q%H_B/XD6=
MAH,EGX>\0:#:6\4&E/'9FZG"W:3>6<A4EVM"-[8_AR>..4\$_#KQ3=?![X@Z
M#H^F-H;W^G+#I.H3Z9!I%]<7!C=625("8SM41@3A5!WG@A-Q^B**`/`?A1\)
MIO[%\:J=)\66ECK&BKIILGM['1S<.%E!\E("`)0KA//8A3\N"0N:W_V6/#VI
M>%AK=K+H;:=I(%N;6ZN=)@TN]NI`'5TEB@8QOL41XE4*&W$8(7<?7Z*`"BBB
M@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`
+"BBB@`HHHH`__]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>release.jpg
<TEXT>
begin 644 release.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``(!`0(!`0("`@("`@("`P4#`P,#
M`P8$!`,%!P8'!P<&!P<("0L)"`@*"`<'"@T*"@L,#`P,!PD.#PT,#@L,#`S_
MVP!#`0("`@,#`P8#`P8,"`<(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`S_P``1"``A`.`#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#]L]9_:]^'
M7A[XT1_#V]\21VWB^6:*!+%[.X`:25`\:^;Y?E9967'S]2!UXKK?B3\2-%^$
M7@F_\1^(;S^S]&TQ%>YN/)DE\H%@H^5%9CRP'`/6OS"_;X^'^M_$K_@HGXNT
M[PZK2:O#:P7T"HY61O(TZ.8["/X\(=H[G%?0'C3]J*']J;_@E?XOU.>6/_A(
MM*M+>QUJ$8!$ZSQ8EQ@860#<,#`.Y1]TUGS-X;VJ^*U_D]+_`'W7W&G*O;QI
MO9V^^R;_``>A],Q_M2>!)?@:?B0-<SX+7KJ/V*X_Y[>1_JO+\W_6?+]SWZ<U
MY_\`\/2/@3_T//\`Y1=0_P#C%?/]A_R@YF_X%_Z>:\]_99_X9/\`^%&Z-_PL
MS_D=,S_;_P#D,=/.?R_^/?\`=?ZO9]W\><UM.-JDXK:+MY[&47>G&;W;:^X^
MXOAQ^WI\*/BYK%UI_AWQ2VI7EE93:A-$NE7J,L$0W2,-T(W$#^$98]@:Z;X'
M?M*^"?VD;"_N?!>MC68=+D2*Z/V2>W,3,"5XE1"<@'D`CBO%_P!C7PM^S5K?
MQ!U"\^$=N)M=L;%DNF9M4PMO*0K`K='8<D`<`FO(O^"9C?\`"A_VQ/BQ\/+J
M3R+:)99(1)P&6UG(1LD#K%-N[<4*W/RO3W6_N>ORM^-Q._)S+I)+[]OG?\+'
MU1XU_;>^%WP[^*1\%ZSXICLO$BSPV[6C6-TZJ\H4Q@RK&8QD.O.[`SSC!KL?
MBW\8?#GP+\%3^(O%6HC2M'MY$BDN#!)-AG;:HVQJS')/85^47Q'\(7_QX\*_
M%/XVP>>%L/%D`MSUV02-)UP?X-UJ.G?ZU]#_`/!4#XY?\+,_9,^$\-FSM/XX
MDBU5XT/#;(`"AZ?\M)QVZK[5FN9THNWOWBFO\235OE<TLE5<?LVEK_AT?XGU
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M_H5Q<^=Y>W?_`*J-\8WKUQG/%7_@%X#NOA?\&_#OA^\U[_A)Y-)LUMTU/R!#
M]JB&?*.T._1-JYW'.W/>OCC_`(+>^7O^%_G?ZGSM0\SK]W_1<].>E*K[M10B
M]W:[T_X8JC[RO+LW^%SW?_AZ1\"?^AY_\HNH?_&*]A^''Q2\/?%[PC!KOAG5
M[+6M*N`"L]L^[:=H8HZ_>1P&&48!ESR!7PCKC?L-IX=NS`MTUT+=S&+;^W/.
M+[3C9YO[O=GIO^7.,\9K5_X(D66KKHWQ#N/]('AQY;:.#S!\CW($A?:>FX(8
M]V/[R>U'V9OK%7\OZ_X!$FTHR[NUNI[S+_P5$^!4,C*WCG#*2"/[&U#@_P#?
MBK.B?\%+_@EXCUJTT^S\:^=>7\Z6\$?]CWZ[Y'8*HR8`!DD<DXK\^OV*_P#A
M1?\`:WBW_A=7W=\']D?\A#KF7SO^/3_ME]_\.]?3GPF\._L8^+/B7H=AX6A\
M_P`1S7D9TV/?KB[IU.Y.9"$ZC/S'''-7"-Y13UO;;S_4JM[KFH]+[GU%X[_:
M=\#_``T^*.C>"];UO[%XE\0"(Z?9_8[B3[1YDC1I\Z(47+J1\S#&.>*[VO@K
M]NS_`)2A_!G_`'-,_P#3A-7WK40]ZBJCWO)?=8)^[5<%M:+^]'`?'/\`:B\"
M_LV)II\:ZY_8HU@R"T_T*XN?.\O;O_U4;XQO7KC.>*\^_P"'I'P)_P"AY_\`
M*+J'_P`8KP3_`(+D8\CX9YZ>9J.?_)6J]O\`\,*_9T\S[^T;O^1@Z]ZFFW*+
MD^[7W%32CRI=5?\`$^S?@A^T7X-_:.T6\U#P9K']LV>GSBWN)/LD]OY<A4,!
MB5$)X(Y`Q57XY?M2^`OV;?[.'C3Q!'HS:MO^RI]EGN'E";=QVQ(Y`&X<D`<U
M@?L8^'?A1IGPTNK_`.$$.SPYJ=XQFDWWA\R=`%/%T=XP,#@`5\B?';P=/_P4
M)_X*`>)O#=K*ZZ1X'T2ZLXI%;Y1/$K*I].;N50?58Z=5M348+I=^B5W_`,#U
M%3LXN4WUM\V[+_@GZ$>#O&&F_$#PKI^MZ/=QWVEZK;I=6MP@($L;#*G!`(^A
M`(Z$9K-^*7Q@\,?!/PP^L>*]<T_0]/7(62YDPTS`%MD:#+2/@$A$!8XX%?-/
M_!'WXP2>*O@3J7@N_P!R:EX'O6B".?G$$S.Z@C_9D$H]AMKR_P#X+!^&+^R^
M-_@3Q'K]EJNJ?#N.!+6:*TE\L),)6>:,/@A))(]F"1\WEG'W#BJ]HSC&#TE:
MS?9JZO\`EZBHW<9.:UC>ZZW7]7]#Z>\&?\%%_@MX]\0PZ7I_CS3UN[C/E_;;
M6YL8B0,X\V>-(P3V!;)/`R:]-^)_Q0T/X->!K[Q)XDOO[-T730AN;GR9)O+W
MNJ+\L:LQRS*.`>M?G7>>$_V2?VA?"D.G>&M5U'X1>))[L+!/K"W5PFU1D^:7
MG>W$;`G!,R,&49X^5OH?]L#P'=?"_P#X)<:MX?O->_X2>32;"QMTU/R!#]JB
M%[#Y1VAWZ)M7.XYVY[U-5\M-S6]TO)W_`,ATES58P>S^]:G6?\/2/@3_`-#S
M_P"474/_`(Q75?!W]MWX8?'WQA_8'A+Q-_:VK&![CR/[.NX/W:8W'=+$J\9'
M&<U\)_LL_P##)_\`PHW1O^%F?\CIF?[?_P`ACIYS^7_Q[_NO]7L^[^/.:^H_
MV+O#O[-FI?$>]U#X/P[_`!#IMF1<2;]4'EP2,`>+H[#D@=`36O(E)Q>N^WI^
M7?R,G)\MUIKU]?ZL>4Q_\IP9/^N`_P#30*\R_P""AGPDU?\`9$^)GBB;P]&4
M\"?%FU,<\`!\FWN%E69H^N`RNN]"1]R5U`X)K]!1^S%X''QP/Q(_L3_BM"NT
MZC]LN.GD^3_JM_E?ZOY?N>_7FM/XP_!/PO\`'WP>=!\7:3%K&E&9+@0O))$4
MD7.UE>-E=3R1P1D$@\$BL'%^SIQ6\59^:;U_KNC=2]^4GL^7[XI6?W_@?%-A
M_P`H.9O^!?\`IYKSW]EG_AD__A1NC?\`"S/^1TS/]O\`^0QT\Y_+_P"/?]U_
MJ]GW?QYS7Z!1_LM^!(O@:?AL-#QX+;KIWVVX_P">WG_ZWS/-_P!9\WW_`&Z<
M5Y__`,.M_@3_`-"-_P"5K4/_`(_6LY7J3DMI._GL9Q5J<8/=-O[SF_V-_&'[
M,^A_$V72_A'<>5XCUNV:-XO+U5O/BCS(1FZ!1<8)Z@FOG'_@HQJ&H?LR_MP7
MWBK208_^$P\.3+N4X^>6VDLW/7JI5'[<XK[6^$W["GPK^!OC:W\1^%O"W]EZ
MS:H\<5Q_:5Y/M5U*L-LDK*<@D<BMGXY?LI^`?VDKC3I?&F@#69-)61+1OMEQ
M;&(/M+#]U(F<[5ZYQCBLZL>;EMTNGZ.]TO+5%4GR\U^MK>JMKZZ'A'[*/[.`
MUC_@EU=>'7A'V[QIIEYJ0!&<S29-NW?M'"?_`*]?(G[*%_>_M&_'SX*^#;M'
M-CX(>5V5NC(EQ+>.<9XR`B?\!'6OUH\.>';/PCX>L=*TZ`6VGZ;;QVEM""6$
M42*%5<DDG``&2<UY]\+OV-OAM\%_B!<^*?#/AF/2]<NTECDN%O;F4;9&#.!&
M\C(N2!]U1CH,"MN=?676Z:6]8WY?SLS+E?U?V77K\[<WY:'BO[97[<7B+]F3
M]H+3O#WB;POHNL?"WQ#:`S2?9'DN[B)E,<\>6D\ERK$$HR<HP!(W9KQ/]L/Q
M[^R=XT^&.KWGA"PA_P"$TDMU@TT:)IMWID<+@Y#O&R1VY7J&.TN0>.0"/T"^
M)OPF\-?&;PQ)HWBG1=/US3I,D17408Q,5*[XV^]&X#$!T(89X(KR[P[_`,$U
M?@AX7UJWO[;P%923VS;D6[OKN\A)QCYHI96C<<]&4BN?DO'EE]_7^D;\UGS1
M^[I_3,O_`()9IK,?[%WAH:P)U'FW!L!,#N^RF5BG7G;G=M_V=N.,5XC_`,%M
MH5N;GX61N,I)<7ZL/4$VN:^\K>WCL[=(HD2**)0B(B[511P``.@%<+\;/V9/
M`_[14FE-XRT3^V&T1I'LC]LN+?R2^S=_JG7=G8OWL]/K6]22G6C4>R:?R7ZO
MJ9T?<BUY/\;GR;^VQ_P3(\.^"?AB/&7PNTI[#4_#*K>7>E22/J$-_"IW.X2X
M,F64<E#E652-I/7V'_@G#^U)I'[0?P-&G0Z?I6A:YX746][INGP);6Y1LE9X
MHE`54<[L@#APW8C/T:$`3;CC&,5YE\+_`-CGX<?!;QY=^)?"WAW^QM7ODDCG
MD@U"Z\J1)&W,ODF0Q!<@$`+A<#&,"LM>6=-[26GD_P#+^NUAK2+7Q+\5_G_7
MK^:7[%?_``HO^UO%O_"ZON[X/[(_Y"'7,OG?\>G_`&R^_P#AWKZ7^&OC#]BS
MP!X]TG6/#MQ]DURPN5DL9O+UV39+T4[7!0]?XABO99?^"7?P*FD9F\#99B23
M_;.H<G_O_3[/_@F%\#=/O(IX?!&R6!Q(C?VSJ!VL#D'!G]:UA)*47+2UMO+]
M1UO><W'K?<^=/^"CGB[3_`/_``49^%>MZM<?9-,TFTT^[NYO+9_*B2^G9FVJ
M"QP`>`"?:OH?_AZ1\"?^AY_\HNH?_&*['XU_L:?#;]HGQ-;ZQXQ\.?VQJ-K;
M"SBF_M"ZM]L09G"[8I%4_,[')&>>M<=_PZW^!/\`T(W_`)6M0_\`C]9T^:-/
MV;[M_>RJEI3YUV2^Y'SC_P`%D_&6F?$/P7\(M<TFX^V:3JT=]=6L_EO'YL3K
M:E6VL`PR#T(!JW;_`/#"OV=/,^_M&[_D8.O>OK#Q_P#L6?#/XH>#_#>@Z[X:
M^W:3X1@:VTF#^T;J+[)&0@*[DE#/Q&G+DGCW-<E_PZW^!/\`T(W_`)6M0_\`
MC]$4HIQ6UVUWL^XFW)1;W2L^V]S$^'G[17P<^$7[)_C;4OA)=QG1O"$,EP8'
M2\4"\G!$*YNAN;>X4<$@5\Q?L*?L_P#Q\\0^#=2\>_#KQ=X6\.Q^*;EX[J75
M(Q+<WAB=LO\`-:S!5WL_0C)'(X%?:>G?\$_?A'I/@/4O#%OX4:+0]7N8;R\M
M1JU]B>6$,(R6\[=@;VX!P3@D$@8])^''PXT7X1^"K#P[X=L5TW1M,0QVULKO
M)Y8+%C\SDL222<DD\U6G/*=WLDOU_P`K=K$Z\BAINV_T_P`[][GYV_L]/XK_
M`&*O^"CL&E>/;_3YKCQVI34+JPR+2Z>[8O'(J^7&!_I"A3\@"Y?'%>[?ME?M
MQ>(OV9/V@M.\/>)O"^BZQ\+?$-H#-)]D>2[N(F4QSQY:3R7*L02C)RC`$C=F
MO<_C#^R?X`^/GB73=8\5Z!_:>IZ.GEV=RE]<VSPJ&W@?N9$SAN1G.,G'6NC^
M)GPE\-?&7PO)HWBG1;#7--?)$5U%O,3%2N^-OO1OAB`Z$,,\$5-W[."TO%O3
MHX]%^)6G/)]))>M^K/S]_;#\>_LG>-/ACJ]YX0L(?^$TDMU@TT:)IMWID<+@
MY#O&R1VY7J&.TN0>.0".AL$UF/\`X(EZD-8$ZC<AL!,#N^RG4HBG7G;G=M_V
M=N.,5](>'?\`@FK\$/"^M6]_;>`K*2>V;<BW=]=WD).,?-%+*T;CGHRD5ZC\
M1_A/X?\`BU\/KKPKK^G)>Z!>I''+9I*]NI6-E=`&C964!D7H1TQTI./[N45N
M[>FCO]XXR_>0D]HN_FS\W_V6?^&3_P#A1NC?\+,_Y'3,_P!O_P"0QT\Y_+_X
M]_W7^KV?=_'G-?3W[&_C#]F?0_B;+I?PCN/*\1ZW;-&\7EZJWGQ1YD(S=`HN
M,$]0372?\.M_@3_T(W_E:U#_`./UTGPF_84^%?P-\;6_B/PMX6_LO6;5'CBN
M/[2O)]JNI5AMDE93D$CD5MSIR<GIOMZ?EW\C%Q?+9:Z]?7^K'KE%%%9F@444
M4`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110
'`4444`?_V3\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
